Dark Forest Capital Management LP Acquires New Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Dark Forest Capital Management LP bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,568 shares of the company’s stock, valued at approximately $839,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMDX. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group during the first quarter worth $35,000. International Assets Investment Management LLC acquired a new position in TransMedics Group during the 2nd quarter worth about $47,000. J.Safra Asset Management Corp grew its position in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC increased its stake in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Amalgamated Bank increased its stake in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after buying an additional 70 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director James R. Tobin sold 20,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the transaction, the director now directly owns 173,146 shares in the company, valued at approximately $27,587,352.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,948,714.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James R. Tobin sold 20,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock worth $9,650,880 over the last quarter. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TMDX. TD Cowen upped their target price on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Robert W. Baird initiated coverage on shares of TransMedics Group in a research note on Tuesday. They issued an “outperform” rating and a $200.00 price objective on the stock. Morgan Stanley lifted their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price target on the stock. Finally, Needham & Company LLC began coverage on TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price target for the company. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $174.30.

TransMedics Group Trading Down 2.5 %

TMDX opened at $144.56 on Friday. The company has a fifty day moving average price of $156.02 and a two-hundred day moving average price of $130.77. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The company has a market cap of $4.82 billion, a P/E ratio of -425.18 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm’s revenue was up 117.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.03) EPS. Analysts predict that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.